FGFR研究进展及其作为药物筛选靶点的前景展望  

progress of FGFR as well as its prospect as drug screening target in the future

作　　者：郭敏红 罗文娟[1] 赵巧[3] 李小颖[1] 刘翠翠[1] 

机构地区：[1]西安交通大学医学院,陕西西安710061 [2]陕西送变电职工医院,陕西西安710014 [3]西安医学院,陕西西安710021

出　　处：《中国妇幼健康研究》2012年第5期690-693,共4页Chinese Journal of Woman and Child Health Research

基　　金：陕西省自然科学基金资助项目（SJ08-ZT10）

摘　　要：碱性成纤维细胞生长因子（bFGF）是成纤维细胞生长因子蛋白（FGFs）家族中的一员。到目前为止，至少有22种FGFs被鉴定，其来自不同的生物体，从线虫、果蝇到鼠类和人类。FGFs具有多种生物学功能，能够调节多种细胞反应。在多种肿瘤的发生中，碱性成纤维细胞生长因子及其受体存在表达异常，其异常表达与子宫内膜癌的发生也具有一定的相关性。该文就成纤维细胞生长因子受体（FGFR）结构、生物学功能及其引发疾病的机理作以综述，并初步提出将FGFR作为靶点实现药物的筛选的预想。Basic fibroblast growth factor （bFGF） is a member of desmocyte fibroblast growth factors （FGFs） protein family. As yet, at least 22 distinct FGFs have been identified in a variety of organisms from nematode and drosophila to mouse and human. FGFs posses muhi-biological functions and can mediate a variety of cellular responses. During embryonic development, the expressions of bFGF and their receptors are abnormal, and the abnormality is associated with the development of endometrial carcinoma to certain degree. This article summarized FGFR＇ s structure, biological functions as weU as the mechanism of disease. Moreover, preconception of FGFR as drug screening target in the future was proposed.

关 键 词：子宫内膜癌 碱性成纤维细胞生长因子 酪氨酸激酶受体 药物靶点 信号转导 

分 类 号：R329[医药卫生—人体解剖和组织胚胎学]